A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)
Clinical trial NCT03835819 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03835819
- Sponsor
- Dana-Farber Cancer Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-01-02
- Primary completion
- 2024-06-04
- Enrollment
- 18
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.